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We report a patient having disseminated tuberculosis (TB) with negative smear and culture for
Mycobacterium tuberculosis, left testicular mass, and an increase in tumour markers; alpha-
fetoprotein (AFP), CA-125, and CA-19-9. The patient was a 53-year-old Caucasian male, pre-
sented with night sweat, weakness, and weight loss. Radiological findings were compatible
with tuberculosis, however, sputum, bronchoalveolar lavage and biopsy materials were nega-
tive for malignancy or tuberculosis. A testicular mass was detected during the physical exam-
ination and orchidectomy material revealed acid-fast bacilli containing caseating granuloma.
The patient responded well to anti-tuberculous therapy; clinical and radiological improve-
ments observed at the end of the treatment period. Tumour markers were also decreased.
Crown Copyright ª 2008 Published by Elsevier Ltd. All rights reserved.Description of case
A 53-year-old male was presented with a 1-month history of
night sweat, weakness, and 2- months’ history of weight
loss (15 kg). He was slim, pale and weak, and his body
temperature was 37.8 C on the day of admission. He was2 304 4403; fax: þ90 312 304
m (M. Ozkan).
08 Published by Elsevier Ltd. All ra heavy smoker and reported using approximately 20 ciga-
rettes per day for the previous 40 years.
A 1 2 cm. left testicular mass was detected by physical
examination, which was also confirmed with ultrasono-
graphic examination. No abnormality was found during the
bronchoscopic examination.
White blood cells were found to be increased
(12.300/mL) in complete blood count. Erythrocyte sedi-
mentation rate was 23 mm/h, and LDH level was 298 U/
L. Urinalysis was normal. HBsAg, HCV and HIV antibodies
were negative. Alpha-fetoprotein (AFP) was marginally
elevated (9.6 ng/mL). CA-125 (412.7 U/mL), and CA-19-9ights reserved.
Table 1 Tumour markers before and after anti-tuberculous therapy
Marker Before anti-tuberculous
therapy
After 2 months
of therapy
After 6 months
of therapy
CA-125 (U/mL)(Normal: <35) 412.7 89.7 6.4
CA-19-9 (U/mL)(Normal: <37) 93.33 35.4 14.45
AFP (ng/mL)(Normal: <8.1) 9.6 8.6 7.6
248 M. Ozkan et al.(93.33 U/mL) levels were obviously high (Table 1).
Sputum, bronchoscopic lavage, and transbronchial biopsy
materials were negative both for microorganisms and
malignancy.Figure 1 Initial posterior-anterior chest radiography showing bila
normal following a 6-month-anti-tuberculous therapy (B). Initial th
infiltration (C). Almost all infiltrations being cleared at the end ofBilaterally diffuse reticulo-nodular infiltrations were
observed in posteroanterior chest radiograms (Fig. 1).
Abdominal computed tomography (CT) indicated para-
vertebral, paraaortic, and abdominal multipleterally diffuse reticulo-nodular infiltration (A). Becoming almost
orax CT scan image showing bilaterally reticulo-nodular miliary
anti-tuberculous therapy (D).
Disseminated tuberculosis 249lymphadenopathies. Chest CT illustrated bilaterally diffuse
reticulo-nodular pattern (Fig. 1).
After consulting the patient, with the department of
urology, left orchidectomy was performed for histopatho-
logical diagnosis of the testicular mass. Histologic exami-
nation of the orchidectomy specimen revealed extended
necrosis with caseous granulomatous inflammation of
possible tuberculous etiology. ZiehleNeelsen staining for
acid-fast bacilli was positive.
An anti-tuberculous therapy, with isoniazid, rifampicin,
ethambutol supplemented by pyrazinamide for the first 2
months, was started on the basis of pathologic findings. The
patient became symptom free in the second month of the
treatment. The abnormalities observed in chest radiog-
raphy and in high resolution CT were almost completely
resolved after 6 months (Fig. 1). Thus, the response to the
treatment also confirmed the diagnosis as disseminated
tuberculosis. Tumour markers decreased to the normal
ranges at the end of the therapy as well (Table 1).
Discussion
Tuberculosis is the leading cause of death due to a single
infectious agent worldwide.1 Although the term ‘‘miliary
TB’’ has been traditionally used for a pathological and
radiological description, currently all forms of progressive
widely disseminated haematogenous TB are being called as
miliary TB, even the classical pathological or radiological
findings are absent.2 Many adult patients with progressive
tuberculosis have accompanying medical conditions that
cause their specific immune responses to wane. Our patient
was not immuncompromised and he had no high risk
condition associated with progressive tuberculosis.
Generally, when M. tuberculosis is identified in any
specimen, other systems of patients with suspected
tuberculosis are not tested. As a result of this inclination,
involvement of multiple organs with TB is probably much
more common than it is recognized; therefore, most of
them are overlooked.2 Abdominal involvement is a rare
form of TB. CA-125 may be used as a marker for diagnosis,
and in the follow-up of the patients with abdominal
tuberculosis.3e6 CA-19-9 is expressed in mucous cells of the
bronchial gland and surface of the bronchiolar surface
epithelium cells in benign pulmonary diseases.7 It has been
reported in several case reports that the level of CA-19-9
increased in various body fluids in patients with tubercu-
losis and decreased after anti-tuberculosis therapy. The
authors suggested that CA-19-9 level may reflect the
activity of pulmonary tuberculosis.7e9 CA-125 and CA-19-9
levels were found to be increased in our case. Plasma levels
of these markers were started to decline after 2 months,
and found within the normal levels at the end of anti-
tuberculous therapy (Table 1). AFP level was only
marginally elevated to 9.6 ng/mL and then decreased to7.6 ng/mL over a six-month period. Therefore, it may not
reflect the disease activity or response to therapy in
tuberculosis. It has been known that tumour markers
significantly decrease following orchidectomy in testicular
tumour cases. In our case the elevation of tumour markers
was considered as a reflection of disseminated tubercu-
losis, so tumour markers did not decreased immediately
after orchidectomy.
Existence of a testicular mass was a coincidence that
helped us to make the accurate diagnosis by an orchid-
ectomy. It is not clear whether the actual cause of elevated
levels of tumour markers is either abdominal or testicular
involvement. To our knowledge this is the first in the
literature where both tumour markers have been investi-
gated simultaneously and found to be elevated in a patient
with disseminated TB. We suggest that measurement of
these markers may achieve a useful non-invasive tool in the
diagnosis of disseminated tuberculosis. It may also be
a useful to screen the response to anti-tuberculous therapy.
However, it is sure that further studies in prospective
design are needed to claim this hypothesis.
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